Toronto Dominion Bank Acquires Shares of 1,909,228 Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Toronto Dominion Bank bought a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 1,909,228 shares of the company's stock, valued at approximately $105,714,000. Toronto Dominion Bank owned 4.99% of Tarsus Pharmaceuticals as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Crowley Wealth Management Inc. acquired a new stake in Tarsus Pharmaceuticals in the 4th quarter valued at about $25,000. R Squared Ltd acquired a new stake in shares of Tarsus Pharmaceuticals in the fourth quarter valued at approximately $53,000. Quarry LP purchased a new position in Tarsus Pharmaceuticals during the fourth quarter worth approximately $166,000. HighTower Advisors LLC acquired a new position in Tarsus Pharmaceuticals during the fourth quarter worth $207,000. Finally, Summit Investment Advisors Inc. boosted its stake in Tarsus Pharmaceuticals by 6.8% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,848 shares of the company's stock worth $213,000 after buying an additional 244 shares during the last quarter. Hedge funds and other institutional investors own 90.01% of the company's stock.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other news, General Counsel Bryan Wahl sold 3,341 shares of the business's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total transaction of $154,654.89. Following the completion of the transaction, the general counsel now directly owns 58,057 shares of the company's stock, valued at approximately $2,687,458.53. The trade was a 5.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Dianne C. Whitfield sold 2,315 shares of the business's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total transaction of $107,161.35. Following the transaction, the insider now owns 50,751 shares of the company's stock, valued at $2,349,263.79. This trade represents a 4.36% decrease in their position. The disclosure for this sale can be found here. Insiders sold 32,542 shares of company stock valued at $1,581,173 in the last 90 days. Company insiders own 8.25% of the company's stock.

Tarsus Pharmaceuticals Trading Down 0.5%

NASDAQ TARS traded down $0.22 during trading on Thursday, hitting $42.97. The stock had a trading volume of 350,700 shares, compared to its average volume of 698,445. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30. The company has a market capitalization of $1.81 billion, a PE ratio of -11.28 and a beta of 0.94. The firm has a 50 day moving average price of $47.88 and a 200 day moving average price of $49.15. Tarsus Pharmaceuticals, Inc. has a twelve month low of $20.08 and a twelve month high of $57.28.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.05. The business had revenue of $78.34 million during the quarter, compared to analyst estimates of $72.50 million. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. As a group, equities research analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Analyst Ratings Changes

TARS has been the subject of several recent analyst reports. Wall Street Zen cut shares of Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday. Oppenheimer increased their price target on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an "outperform" rating in a report on Wednesday, January 22nd. Barclays reduced their price objective on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. HC Wainwright reaffirmed a "buy" rating and set a $73.00 target price on shares of Tarsus Pharmaceuticals in a research note on Wednesday, February 26th. Finally, The Goldman Sachs Group boosted their price target on shares of Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the company a "neutral" rating in a research note on Monday, May 5th. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $66.33.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.